Amphastar Pharmaceuticals (AMPH) EBITDA Margin (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted EBITDA Margin of 21.6% for Q2 2026, up 171.3% on a QoQ basis from 7.96% in Q1 2026, and down 258.0% year-over-year from 13.67% in Q2 2025.
Powered by 
Analysis
Amphastar Pharmaceuticals (AMPH) EBITDA Margin (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals has reported EBITDA Margin for 14 years, with the latest figure at 21.6% in Q2 2026.
- On a quarterly basis, EBITDA Margin fell 258.0% year-over-year to 21.6% in Q2 2026; TTM through Jun 2026 was 15.66%, a 948.0% decrease from a year earlier, with the FY2025 full-year figure at 19.5%, down 856.0% from the prior year.
- EBITDA Margin was 21.6% for Q2 2026 at Amphastar Pharmaceuticals, up from 7.96% in the prior quarter.
- The five-year high for EBITDA Margin was 40.25% in Q3 2023, with the low at 7.96% in Q1 2026.
- Average EBITDA Margin over 5 years is 23.65%, with a median of 24.03% recorded in 2023.
- The sharpest annual moves came in 2023 and 2025: EBITDA Margin surged 2092 bps in 2023, then tumbled 1664 bps in 2025.
- Over 5 years, EBITDA Margin stood at 28.02% in 2022, then rose by 8 bps to 30.31% in 2023, then retreated by 20 bps to 24.2% in 2024, then slipped by 20 bps to 19.45% in 2025, then advanced by 11 bps to 21.6% in 2026.
- The last three EBITDA Margin figures came in at 21.6% (Q2 2026), 7.96% (Q1 2026), and 19.45% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 25.95% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -134.08% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 15.21% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 9.72% |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.60% |
| Mar 31, 2026 | 7.96% |
| Dec 31, 2025 | 19.45% |
| Sep 30, 2025 | 13.20% |
| Jun 30, 2025 | 24.19% |
| Mar 31, 2025 | 21.87% |
| Dec 31, 2024 | 24.20% |
| Sep 30, 2024 | 29.83% |
| Jun 30, 2024 | 30.27% |
| Mar 31, 2024 | 27.94% |
| Dec 31, 2023 | 30.31% |
| Sep 30, 2023 | 40.25% |
| Jun 30, 2023 | 25.32% |
| Mar 31, 2023 | 23.88% |
| Dec 31, 2022 | 28.02% |
| Sep 30, 2022 | 19.34% |
| Jun 30, 2022 | 20.10% |
| Mar 31, 2022 | 17.96% |
| Dec 31, 2021 | 20.06% |
| Sep 30, 2021 | 22.08% |